Equity Overview
Price & Market Data
Price: $35.58
Daily Change: +$0.95 / 2.67%
Daily Range: $34.07 - $36.00
Market Cap: $4,034,444,800
Daily Volume: 773,284
Performance Metrics
1 Week: 2.07%
1 Month: 4.83%
3 Months: -8.56%
6 Months: 46.30%
1 Year: 87.26%
YTD: 1.43%
Company Details
Employees: 100
Sector: Commercial services
Industry: Miscellaneous commercial services
Country:
Details
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.